Literature DB >> 1350344

Difficulties in localization and treatment of insulinomas in type 1 multiple endocrine adenomatosis (MEA).

P H Winocour1, K J Moriarty, C N Hales, J Adams, R Reeve, D Wynick, D Allison, S R Bloom, D C Anderson.   

Abstract

A 15 year old girl with a family history of type 1 multiple endocrine adenomatosis presented with reversible neurological disturbances, hypoglycaemia and hyperinsulinaemia. Initial radiology was normal, but portal venous sampling suggested an insulinoma in the tail of the pancreas which was removed with conservation of the spleen. Hypoglycaemia persisted despite high doses of diazoxide and intravenous dextrose. A second laparotomy revealed a pancreatic endocrine tumour and sub-total pancreatectomy was performed. Histology revealed islet cell microadenomatosis. Hypoglycaemia persisted despite treatment with somatostatin analogues and 40% intravenous dextrose was required to maintain normoglycaemia. A possible lesion near the splenic hilum on computed tomographic scan was reported as a splenunculus although further peripheral, hepatic and portal venous sampling suggested hepatic or systemic lesions. A positron emission scan and selective visceral angiography suggested a lesion in the left upper quadrant. Acute lactic acidosis, rhabdomyolysis and renal failure supervened. Post mortem revealed the putative 'splenunculus' to be a residual insulinoma, whilst the splenic vein was thrombosed, accounting in part for discrepant venous sampling data. Hyperinsulinaemia in type 1 multiple endocrine adenomatosis may require more aggressive surgical and hormonal intervention than when dealing with solitary insulinomas. Insulinomas may mimic developmental abnormalities on computed tomographic scanning.

Entities:  

Mesh:

Year:  1992        PMID: 1350344      PMCID: PMC2399250          DOI: 10.1136/pgmj.68.797.196

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  8 in total

1.  Beta-islet cell tumors of the pancreas: results of a study on 1,067 cases.

Authors:  P Stefanini; M Carboni; N Patrassi; A Basoli
Journal:  Surgery       Date:  1974-04       Impact factor: 3.982

2.  Nesidioblastosis in familial endocrine adenomatosis.

Authors:  J E Vance; R W Stoll; A E Kitabchi; R H Williams; F C Wood
Journal:  JAMA       Date:  1969-03-03       Impact factor: 56.272

Review 3.  Multiple endocrine syndromes--a nightmare for the endocrinologic radiologist.

Authors:  J L Doppman
Journal:  Semin Roentgenol       Date:  1985-01       Impact factor: 0.800

4.  New somatostatin molecule for management of endocrine tumours.

Authors:  S Bonfils
Journal:  Gut       Date:  1985-05       Impact factor: 23.059

5.  Suppression of pancreatic endocrine tumour secretion by long-acting somatostatin analogue.

Authors:  R G Long; A J Barnes; T E Adrian; C N Mallinson; M R Brown; W Vale; J E Rivier; N D Christofides; S R Bloom
Journal:  Lancet       Date:  1979-10-13       Impact factor: 79.321

6.  Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins.

Authors:  W J Sobey; S F Beer; C A Carrington; P M Clark; B H Frank; I P Gray; S D Luzio; D R Owens; A E Schneider; K Siddle
Journal:  Biochem J       Date:  1989-06-01       Impact factor: 3.857

7.  Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995).

Authors:  L K Kvols; M Buck; C G Moertel; A J Schutt; J Rubin; M J O'Connell; R G Hahn
Journal:  Ann Intern Med       Date:  1987-08       Impact factor: 25.391

Review 8.  Multiple endocrine neoplasia syndromes.

Authors:  C J Lips; H F Vasen; C B Lamers
Journal:  Crit Rev Oncol Hematol       Date:  1984       Impact factor: 6.312

  8 in total
  1 in total

1.  Metabolic acidosis as a complication of intravenous dextrose administration in a patient with insulinoma.

Authors:  Agustín Ramos-Prol; Maribel del Olmo-García; Antonia Pérez-Lázaro; María Caballero-Soto; María Argente-Pla; Beatriz León-de Zayas; Juan Francisco Merino-Torres
Journal:  Endocrine       Date:  2010-10-23       Impact factor: 3.633

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.